CymaBay Therapeutics, Inc. Stock price

Equities

CBAY

US23257D1037

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-21 pm EDT 5-day change 1st Jan Change
32.48 USD +0.03% Intraday chart for CymaBay Therapeutics, Inc. 0.00% +37.51%
Sales 2024 * - Sales 2025 * 157M Capitalization 3.73B
Net income 2024 * -129M Net income 2025 * -178M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 23.7 x
P/E ratio 2024 *
-30.1 x
P/E ratio 2025 *
-24.2 x
Employees 101
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.38%
More Fundamentals * Assessed data
Dynamic Chart
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition MT
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc.. CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26 MT
UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25 MT
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform MT
More news
1 day+0.03%
1 week+0.03%
Current month+0.90%
1 month+0.50%
3 months+32.73%
6 months+115.53%
Current year+37.51%
More quotes
1 month
32.16
Extreme 32.16
32.50
Current year
22.11
Extreme 22.11
32.50
1 year
7.26
Extreme 7.2609
32.50
3 years
1.67
Extreme 1.6701
32.50
5 years
1.21
Extreme 1.21
32.50
10 years
0.82
Extreme 0.8201
32.50
More quotes
Date Price Change Volume
24-03-21 32.48 +0.03% 8,356,254
24-03-20 32.47 -0.03% 1,518,195

Delayed Quote Nasdaq, March 21, 2024 at 04:00 pm EDT

More quotes
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock CymaBay Therapeutics, Inc. - Nasdaq